DNER and acute myeloid leukemia: Currently, various BET inhibitors have been developed and few of them are under investigation in clinical trials.15, 16 However, while BET inhibitors were consistently described as highly effective drugs in in vitro experiments, few in vivo observations and early clinical trial reports had already posed some concerns regarding the potential development of resistance to BET inhibitors, when administrated as single agents.16 In the case of AML, for instance, treatment with BET inhibitors promotes resistance through the up‐regulation of BET target genes.17